KRAS and melanoma: However, further studies have shown that B-Raf–specific inhibitors paradoxically activate the MAPK cascade in melanoma cells expressing oncogenic mutant N- or K-Ras via a mechanism that involves C-Raf hyperactivation (Heidorn et al., 2010; Cho et al., 2012a).